双氯芬酸使用与心血管风险:系列全国性队列研究
该研究基于丹麦1996-2016年全国登记数据,采用模拟试验设计比较双氯芬酸与其他传统非甾体抗炎药、对乙酰氨基酚及未用药者的心血管风险。结果显示,双氯芬酸启动者30天内主要不良心血管事件发生率较未启动者高50%,较对乙酰氨基酚或布洛芬高20%,较萘普生高30%,且上消化道出血风险亦增加。
要点
- 双氯芬酸启动者30天主要不良心血管事件风险较未用药者高50%。
- 双氯芬酸风险高于对乙酰氨基酚、布洛芬和萘普生。
- 双氯芬酸还增加上消化道出血风险,与萘普生相当。
核心结论
- 与未使用、对乙酰氨基酚或其他传统非甾体抗炎药相比,双氯芬酸存在心血管健康风险。
研究设计与样本
- 系列252项全国性队列研究,模拟临床试验严格设计(模拟试验设计)。
- 基于丹麦1996-2016年全国人口健康登记数据。
- 纳入无恶性肿瘤、精神分裂症、痴呆或心血管、肾脏、肝脏、溃疡疾病的成人(低基线风险)。
主要发现
- 双氯芬酸启动者30天内主要不良心血管事件发生率较未启动者高50%(发生率比1.5,95%CI 1.4-1.7)。
- 较对乙酰氨基酚或布洛芬启动者高20%(均为1.2,95%CI 1.1-1.3)。
- 较萘普生启动者高30%(1.3,95%CI 1.1-1.5)。
- 双氯芬酸启动者复合终点各组分发生率均增加:房颤/房扑1.2(1.1-1.4)、缺血性卒中1.6(1.3-2.0)、心力衰竭1.7(1.4-2.0)、心肌梗死1.9(1.6-2.2)、心源性死亡1.7(1.4-2.1)。
- 双氯芬酸低剂量启动者风险亦增加;相对风险在低/中度基线风险者(如糖尿病)最高,绝对风险在高基线风险者(如既往心肌梗死或心力衰竭)最高。
关键数值与推荐
- 双氯芬酸启动者30天内主要不良心血管事件发生率较未启动者高50%(发生率比1.5,95%CI 1.4-1.7)。
- 较对乙酰氨基酚或布洛芬启动者高20%(均为1.2,95%CI 1.1-1.3)。
- 较萘普生启动者高30%(1.3,95%CI 1.1-1.5)。
- 上消化道出血风险较未启动者增加约4.5倍,较布洛芬或对乙酰氨基酚增加2.5倍。
临床怎么用
- 临床处方双氯芬酸时应评估心血管风险,尤其在高基线风险患者中。
- 需告知患者双氯芬酸相关心血管及消化道出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the cardiovascular risks of diclofenac initiation compared with initiation of other traditional non-steroidal anti-inflammatory drugs, initiation of paracetamol, and no initiation. DESIGN: Series of 252 nationwide cohort studies, each mimicking the strict design criteria of a clinical trial (emulated trial design). SETTING: Danish, nationwide, population based health registries (1996-2016). PARTICIPANTS: Individuals eligible for inclusion were all adults without malignancy; schizophrenia; dementia; or cardiovascular, kidney, liver, or ulcer diseases (that is, with low baseline risk). The study included 1 370 832 diclofenac initiators, 3 878 454 ibuprofen initiators, 291 490 naproxen initiators, 764 781 healthcare seeking paracetamol initiators matched by propensity score, and 1 303 209 healthcare seeking non-initiators also matched by propensity score. MAIN OUTCOME MEASURES: Cox proportional hazards regression was used to compute the intention to treat hazard ratio (as a measure of the incidence rate ratio) of major adverse cardiovascular events within 30 days of initiation. RESULTS: The adverse event rate among diclofenac initiators increased by 50% compared with non-initiators (incidence rate ratio 1.5, 95% confidence interval 1.4 to 1.7), 20% compared with paracetamol or ibuprofen initiators (both 1.2, 1.1 to 1.3), and 30% compared with naproxen initiators (1.3, 1.1 to 1.5). The event rate for diclofenac initiators increased for each component of the combined endpoint (1.2 (1.1 to 1.4) for atrial fibrillation/flutter, 1.6 (1.3 to 2.0) for ischaemic stroke, 1.7 (1.4 to 2.0) for heart failure, 1.9 (1.6 to 2.2) for myocardial infarction, and 1.7 (1.4 to 2.1) for cardiac death) as well as for low doses of diclofenac, compared with non-initiators. Although the relative risk of major adverse cardiovascular events was highest in individuals with low or moderate baseline risk (that is, diabetes mellitus), the absolute risk was highest in individuals with high baseline risk (that is, previous myocardial infarction or heart failure). Diclofenac initiation also increased the risk of upper gastrointestinal bleeding at 30 days, by approximately 4.5-fold compared with no initiation, 2.5-fold compared with initiation of ibuprofen or paracetamol, and to a similar extent as naproxen initiation. CONCLUSIONS: Diclofenac poses a cardiovascular health risk compared with non-use, paracetamol use, and use of other traditional non-steroidal anti-inflammatory drugs.
引用
- Schmidt M, Sørensen HT, Pedersen L, et al. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ. 2018. PMID: 30181258. doi:10.1136/bmj.k3426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。